GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) was down 8.4% on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.16 and last traded at $4.17. Approximately 959,968 shares changed hands during trading, a decline of 25% from the average daily volume of 1,288,451 shares. The stock had previously closed at $4.55.
GDRX has been the topic of several other research reports. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target for the company. Morgan Stanley dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Finally, Barclays lowered their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.38.
Check Out Our Latest Report on GoodRx
Institutional Investors Weigh In On GoodRx
GoodRx Stock Performance
The business’s fifty day moving average price is $4.68 and its 200-day moving average price is $6.53. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market capitalization of $1.61 billion, a PE ratio of -140.67, a P/E/G ratio of 3.43 and a beta of 1.27.
About GoodRx
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Articles
- Five stocks we like better than GoodRx
- Basic Materials Stocks Investing
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Comparing and Trading High PE Ratio Stocks
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What is a Secondary Public Offering? What Investors Need to Know
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.